Recent News

• 04.08.2025 - Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial
• 04.02.2025 - Cartesian Therapeutics Announces New Employment Inducement Grants
• 04.01.2025 - Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
• 03.13.2025 - Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
• 03.06.2025 - Cartesian Therapeutics Announces New Employment Inducement Grant
• 02.18.2025 - Cartesian Therapeutics to Participate in Upcoming Investor Conferences
• 02.06.2025 - Cartesian Therapeutics Announces New Employment Inducement Grants
• 01.27.2025 - Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis

Recent Filings

• 04.08.2025 - 8-K Current report
• 04.08.2025 - EX-99.1 EX-99.1
• 03.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.13.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.13.2025 - 8-K Current report
• 03.13.2025 - EX-99.1 EX-99.1
• 03.03.2025 - 8-K Current report
• 03.03.2025 - EX-99.1 EX-99.1
• 02.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.27.2025 - EX-99.1 EX-99.1